Summary:
Background: Seborrheic dermatitis is a common papulosquamous
dermatosis and occurring in 2% to 5% of the
population. The prevalence of seborrheic dermatitis among
HIV-positive and AIDS patients between 34% and 83%. The
anti-inflammatory activity of oral itraconazole and efficacy
on Malessezia suggests that itraconazole capsule will be the
first oral treatment option in future in seborrheic dermatitis.
Unfortunately there is no data base study with the efficacy
of oral itraconazole for the treatment of seborrheic
dermatitis over Bangladeshi people.